Tradestie Institutional Equity Comparison Engine

SLS vs LCTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while SLS counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SLS trades at N/M Forward P/E with 0.0% operating margin (-82.5% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, SLS sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
SLS N/M vs LCTX 30.7x Fwd P/E
Growth & Margin Winner LCTX
Op Margin 0.0% vs -280.3% ยท YoY -82.5% vs -61.0%
Momentum & Technical Winner SLS
1Y +798.7% vs -54.9% ยท 52W Pos 52% vs 0%
Options & Structure Winner SLS
CONSOLIDATION (5th %ile IV) vs BREAKDOWN (<1st %ile IV)
SLS NASDAQ
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$13.66
-8.08% 1D
Market Cap $3.0B
1M Return +20.35%
1Y Return +798.68%
Forward P/E N/M
Unified AI Score
33.6 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 48.9
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
1M Return -21.63%
1Y Return -54.86%
Forward P/E 30.7x
Unified AI Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SLS +798.68% LCTX -54.86% Spread: +853.54 pp (SLS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SLS Revenue LCTX Revenue SLS Op. Margin LCTX Op. Margin Margin Edge
FY2018 N/A $0M N/A -837.9% LCTX
FY2019 N/A $0M N/A -1106.0% LCTX
FY2020 $0M $0M -893.8% -1448.4% SLS
FY2021 $10M $0M -332.8% -1133.6% SLS
FY2022 $0M $10M -4195.0% -153.2% LCTX
FY2023 N/A $10M N/A -276.5% LCTX
FY2024 N/A $10M N/A -226.1% LCTX
FY2025 N/A $10M N/A -251.6% LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SLS (3) vs LCTX (7)
Institutional Metric SLS LCTX Criterion Row Winner
Market Capitalization Scale $3.0B $207.4M Larger Scale SLS
Trailing P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY) Growth -82.5% -61.0% Higher Growth LCTX
Operating Margin (TTM) Profitability 0.0% -280.3% Higher Margin SLS
Net Profit Margin Profitability 0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency -40.3% 4.3% Higher ROE LCTX
52-Week Range Position Momentum 52% ($1โ€“$25) 0% ($1โ€“$2) Stronger Trend SLS
Beta / 30D Volatility Risk Regime 1.91ฮฒ ยท 550% Vol 1.39ฮฒ ยท 79% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 33.6 / 100 (SELL) 54.9 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SLS vs LCTX Buy Guide
SLS CONSOLIDATION
102d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SLS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
7d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SLS nor LCTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.